La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Sonnet BioTherapeutics Holdings Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Sonnet BioTherapeutics Holdings ha un patrimonio netto totale di $2.6M e un debito totale di $0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente $5.8M e $3.2M.

Informazioni chiave

Rapporto debito/patrimonio netto

US$0

Debito

Indice di copertura degli interessi	n/a
Contanti	US$3.55m
Patrimonio netto	US$2.62m
Totale passività	US$3.18m
Totale attività	US$5.80m

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Sonnet BioTherapeutics regains compliance with Nasdaq's minimum bid price requirement

Oct 04

Sonnet BioTherapeutics announces 1-for-14 reverse stock split

Sep 16

Sonnet gets clearance to start phase 1b/2a trial of SON-080 in Australia

Jul 22

We're A Little Worried About Sonnet BioTherapeutics Holdings' (NASDAQ:SONN) Cash Burn Rate

Dec 19

Sonnet Bio issued U.S. patent for its albumin binding technology

Jun 08

Sonnet shares rise after completing licensing agreement with New Life Therapeutics

May 03

Sonnet BioTherapeutics reports FY results

Dec 17

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( $5.1M ) di SONN superano le sue passività a breve termine ( $3.1M ).

Passività a lungo termine: Le attività a breve termine di SONN ( $5.1M ) superano le sue passività a lungo termine ( $68.8K ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: SONN è esente da debiti.

Riduzione del debito: SONN al momento non ha debiti, tuttavia non possiamo fare confronti con 5 anni fa perché non abbiamo dati per quel periodo.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: SONN ha meno di un anno di cash runway in base al suo attuale free cash flow.

Previsione Cash Runway: SONN ha meno di un anno di liquidità disponibile se il flusso di cassa libero continua a ridursi ai tassi storici del 17.9 % ogni anno

Sonnet BioTherapeutics Holdings Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Nasdaq Determines to Delist Sonnet BioTherapeutics Holdings Securities

Nasdaq Determines to Delist Sonnet BioTherapeutics Holdings Securities

Sonnet BioTherapeutics Holdings Receives Non-Compliance Notice From Nasdaq

Sonnet BioTherapeutics Regains Nasdaq Minimum Bid Price Compliance

Nasdaq Listing Qualifications Staff Grants an Extension to Sonnet

Sonnet BioTherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Recent updates

Nasdaq Determines to Delist Sonnet BioTherapeutics Holdings Securities

Nasdaq Determines to Delist Sonnet BioTherapeutics Holdings Securities

Consensus EPS estimates upgraded to US$1.95 loss

Sonnet Biotherapeutics Holdings, Inc. to Present SB221 as A Trial in Progress At the Asco 2024 Annual Meeting

Sonnet BioTherapeutics Holdings, Inc. Announces Updated Clinical Data for Son-1010 as Monotherapy or Combined with an Anti-Pd-L1, Along with an Increase in the Dose-Escalation Target

Consensus revenue estimates increase by 42%, EPS downgraded

Second quarter 2024 earnings released: EPS: US$0.079 (vs US$7.55 loss in 2Q 2023)

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Sonnet BioTherapeutics Holdings Receives Non-Compliance Notice From Nasdaq

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Share price stability

Sonnet BioTherapeutics Regains Nasdaq Minimum Bid Price Compliance

Sonnet Biotherapeutics Announces FDA Acceptance of the Company's IND for the SB221 Clinical Trial of SON-1010 Combined with Atezolizumab in the US

Third quarter 2023 earnings released: US$0.13 loss per share (vs US$1.82 loss in 3Q 2022)

Sonnet BioTherapeutics Holdings, Inc., Annual General Meeting, Aug 31, 2023

Sonnet Biotherapeutics Holdings, Inc. Announces Regulatory Approval for Initiation of A Clinical Trial of Son-1010 Combined with Atezolizumab

Founder recently bought US$83k worth of stock

Price target decreased by 13% to US$10.35

Consensus revenue estimates decrease by 50%, EPS upgraded

Sonnet BioTherapeutics Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $14.999777 million.

Sonnet BioTherapeutics Holdings, Inc. has completed a Follow-on Equity Offering.

Sonnet BioTherapeutics Announces Successful Completion of Two IND-Enabling Toxicology Studies with SON-1210 in Non-Human Primates

Sonnet BioTherapeutics Holdings, Inc. Announces Pharmacokinetic and Pharmacodynamic Data in A Phase 1 Dose-Escalation Trial of SON-1010

Price target decreased to US$25.00

Sonnet BioTherapeutics Holdings, Inc. Announces Interim Data in Two Phase 1 Dose-Escalation Trials of Son-1010

Nasdaq Listing Qualifications Staff Grants an Extension to Sonnet

Sonnet BioTherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Sonnet BioTherapeutics regains compliance with Nasdaq's minimum bid price requirement

Sonnet BioTherapeutics Holdings Inc. Appoints Lori McNeill to the Board of Directors

Sonnet BioTherapeutics Announces Progress in Two Phase 1 Dose-Escalation Trials of SON-1010

Sonnet BioTherapeutics announces 1-for-14 reverse stock split

Sonnet BioTherapeutics Holdings Receives Non-Compliance Letter from Nasdaq

Consensus forecasts updated

Sonnet BioTherapeutics Holdings, Inc. announced that it has received $2.25 million in funding

Sonnet gets clearance to start phase 1b/2a trial of SON-080 in Australia

Price target decreased to US$2.25

Sonnet BioTherapeutics Holdings, Inc., Annual General Meeting, Jun 02, 2022

Nasdaq Grants Extension to Sonnet BioTherapeutics Holdings Till October 03, 2022 to Regain Compliance

We're A Little Worried About Sonnet BioTherapeutics Holdings' (NASDAQ:SONN) Cash Burn Rate

Sonnet BioTherapeutics Holdings, Inc. Selects Novel Development Candidate After Completing Comparative Studies in a Mouse Melanoma Model

Sonnet BioTherapeutics Holdings, Inc. has completed a Follow-on Equity Offering.

High number of new directors

Sonnet Bio issued U.S. patent for its albumin binding technology

Sonnet shares rise after completing licensing agreement with New Life Therapeutics

New 90-day low: US$2.07

New 90-day high: US$3.10

Sonnet BioTherapeutics reports FY results

New 90-day high: US$2.98

New 90-day low: US$2.42

New 90-day low - US$2.46

New 90-day low - US$2.63

SONNET BioTherapeutics, Inc. completed the acquisition of Chanticleer Holdings, Inc. (NasdaqCM:BURG) in a reverse merger transaction.

Sonnet BioTherapeutics Holdings, Inc. completed the acquisition of Relief Therapeutics SA from Relief Therapeutics Holding AG (SWX:RLF).

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Analisi della pista di contanti

Scoprire le aziende sane